Core Points - PetVivo Holdings, Inc. will hold a conference call on August 14, 2025, to discuss its fiscal first quarter results for the period ending June 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary, PetVivo Animal Health, Inc., and is dedicated to the manufacturing, commercialization, and licensing of biomedical devices for animals [4] - The company holds a portfolio of twelve patents and six trade secrets that protect its biomaterials and products [5] Conference Call Details - The conference call will take place at 5:00 p.m. Eastern time, with a toll-free dial-in number provided for participants [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - Digital Landia, in collaboration with PetVivo Holdings and its subsidiary, is set to launch AgenticPet.ai, the first autonomous pet care AI ecosystem, on May 23, 2025, aimed at transforming pet health and wellness through specialized AI agents [1][2] Group 1: Technology and Innovation - AgenticPet.ai utilizes multi-agent technology to create self-learning AI agents that provide insights into pet health, behavior, and nutrition [2][3] - The platform features specialized agents for veterinary diagnostics, behavioral analysis, nutritional advice, emotional wellness, and IoT data integration, enhancing comprehensive pet care [5][4] - The AI agents undergo rigorous digital certification exams to ensure expert-level mastery in various domains related to pet care [3] Group 2: Business Model and Market Strategy - AgenticPet.ai will adopt a tiered pricing structure, including a freemium tier, a premium subscription at $9.95/month, and an elite package at $24.95/month, making the technology accessible to a wide range of pet owners [4][5] - The platform is expected to onboard 100,000 freemium users within six months of launch, with a conservative estimate of a 10% conversion rate to paid subscriptions, potentially generating nearly $2 million in annual recurring revenue [7] Group 3: Strategic Positioning - PetVivo Holdings aims to align its clinically proven therapies with the innovative AI technology of AgenticPet.ai, enhancing its visibility and value in the veterinary care market [8] - The company focuses on leveraging human therapies for companion animals, which allows for a quicker market entry compared to more regulated pharmaceuticals [10]